Business Description
Level Bio AB
ISIN : SE0000885501
Total Employee Number:
10Compare
Compare
Traded in other countries / regions
LEVBIO.Sweden4MB.Germany IPO Date
2024-05-29Description
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.73 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 4.27 | |||||
Debt-to-EBITDA | -3.78 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.76 | |||||
Beneish M-Score | -3.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.4 | |||||
3-Year EBITDA Growth Rate | -111.8 | |||||
3-Year EPS without NRI Growth Rate | -6.8 | |||||
3-Year FCF Growth Rate | -33.6 | |||||
3-Year Book Growth Rate | -69.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.55 | |||||
9-Day RSI | 48.52 | |||||
14-Day RSI | 49.34 | |||||
3-1 Month Momentum % | -14.1 | |||||
6-1 Month Momentum % | -33.66 | |||||
12-1 Month Momentum % | -23.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.01 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 91.73 | |||||
Days Sales Outstanding | 51.02 | |||||
Days Payable | 37.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -3.2 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.64 | |||||
Operating Margin % | -8.08 | |||||
Net Margin % | -8.57 | |||||
EBITDA Margin % | -1.58 | |||||
FCF Margin % | -1.11 | |||||
OCF Margin % | -1.11 | |||||
ROE % | -178.09 | |||||
ROA % | -21.4 | |||||
ROIC % | -20.99 | |||||
3-Year ROIIC % | 19.22 | |||||
ROC (Joel Greenblatt) % | -5294.92 | |||||
ROCE % | -127.68 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 38.29 | |||||
PS Ratio | 0.52 | |||||
PB Ratio | 38 | |||||
EV-to-EBIT | -6.53 | |||||
EV-to-EBITDA | -33.47 | |||||
EV-to-Revenue | 0.53 | |||||
EV-to-FCF | -33.23 | |||||
Earnings Yield (Greenblatt) % | -15.32 | |||||
FCF Yield % | -2.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Level Bio AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 34.368 | ||
| EPS (TTM) (kr) | 0.07 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 60.47 | ||
| 14-Day RSI | 49.34 | ||
| 14-Day ATR (kr) | 0.030751 | ||
| 20-Day SMA (kr) | 0.262 | ||
| 12-1 Month Momentum % | -23.43 | ||
| 52-Week Range (kr) | 0.222 - 0.55 | ||
| Shares Outstanding (Mil) | 68.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Level Bio AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Level Bio AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 171 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 51 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | 0.28 (-0.72%) | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 0.28 (-0.72%) | ||
| General meeting for 2026 | 2026-05-20 14:00 | 0.28 (-2.13%) | ||
| Annual report for 2025 | 2026-05-05 | 0.29 (+0.70%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 0.35 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 0.30 (-10.24%) | ||
| Third quarter earnings results for 2025 | 2025-10-23 | 0.38 (+6.82%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-21 09:00 | 0.30 (+0.00%) |
Show
Entries
Level Bio AB Frequently Asked Questions
What is Level Bio AB(NGM:LEVBIO)'s stock price today?
The current price of NGM:LEVBIO is kr0.27. The 52 week high of NGM:LEVBIO is kr0.55 and 52 week low is kr0.22.
When is next earnings date of Level Bio AB(NGM:LEVBIO)?
The next earnings date of Level Bio AB(NGM:LEVBIO) is 2026-10-22.
Does Level Bio AB(NGM:LEVBIO) pay dividends? If so, how much?
Level Bio AB(NGM:LEVBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Level Bio AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers